OBI Pharma and AP Biosciences Sign Technology Collaboration Agreement to Develop Next-Generation ADC
2025.Aug.31
News
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors
2025.Jul.22
News
OBI Pharma Showcases Innovative Pipeline, Platforms, and Technologies at BIO Asia–Taiwan 2025
GlycOBI® and HYPrOBI™ Drive the Advancement of Bispecific, Dual-Payload ADCs
2025.Jun.10
News
OBI Pharma Showcases Next-Generation ADC Development at 2025 World ADC Asia Summit
2025.Jun.06
News
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
2025.Mar.18
News
New Chairman of OBIGEN Pharma: OBI Pharma CEO Heidi Wang Takes Over
2025.Mar.12
News
OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award
Dr. Heidi Wang Accepts Award on Behalf of OBI Pharma at ADC Asia Congress 2025 and Gives a Presentation
2025.Feb.19
News
Invited to the 2025 Healthcare Conference in Taipei
Dr. Heidi Wang engaged in discussions on Regulatory Landscape and International Partnerships in Pharma and Diagnostics
2024.Dec.31
News
OBI Pharma's OBI-992 Research Paper Featured on Cover and Selected as a First Disclosure Article in Molecular Cancer Therapeutics Journal
2024.Dec.23
News
OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production
Events
Investor
Scientific
BIO ASIA-TAIWAN 2025
2025.Jul.23 ~ 2025.Jul.27
Taipei Nangang Exhibition Center, Hall 1 (TaiNEX1)
Event Time2025.Jul.23 ~ 2025.Jul.27
Event LocationTaipei Nangang Exhibition Center, Hall 1 (TaiNEX1)
